28077790 |
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
Levis, M,
Nguyen, B,
Williams, AB,
Small, D,
Brown, P,
Li, L,
Young, DJ,
Ma, H
|
Oncotarget |
2017 |
26108694 |
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
Shah, NP,
Stecula, A,
Smith, CC,
Sali, A,
Lin, K
|
Leukemia |
2015 |
28576946 |
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Baer, MR,
Larrosa-Garcia, M
|
Mol. Cancer Ther. |
2017 |
15256420 |
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518
Gilliland, DG,
Lokker, NA,
Curley, DP,
Clark, JJ,
Giese, NA,
Yu, JC,
Cools, J
|
Blood |
2004 |
12124172 |
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
Gilliland, DG,
Boulton, CL,
Kelly, LM,
Duclos, N,
Scarborough, RM,
Li, J,
Neuberg, D,
Amaral, SM,
Sullivan, CM,
Hollenbach, S,
Pandey, A,
Lokker, NA,
Williams, I,
Apatira, M,
Abe, K,
Curley, DP,
Giese, NA,
Yu, JC
|
Cancer Cell |
2002 |
23392356 |
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
Yu, C,
Albers, C,
Verbeek, M,
Duyster, J,
Leischner, H,
Illert, AL,
von Bubnoff, N,
Peschel, C
|
Leukemia |
2013 |
22354205 |
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
Pearson, AD,
Avery, S,
Workman, P,
Faisal, A,
Mair, D,
Atrash, B,
Blagg, J,
Bavetsias, V,
Linardopoulos, S,
Mirabella, F,
Valenti, M,
Eccles, SA,
Moore, AS,
de Haven Brandon, A,
Sun, C,
Swansbury, J,
Gonzalez de Castro, D,
Raynaud, FI
|
Leukemia |
2012 |
30651634 |
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Schlenk, RF,
Levis, MJ,
Daver, N,
Russell, NH
|
Leukemia |
2019 |
16990784 |
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248)
Braziel, RM,
McGreevey, L,
Schittenhelm, MM,
Griffith, DJ,
O'Farrell, AM,
Bainbridge, T,
Heinrich, MC,
Tyner, JW,
Cherrington, JM,
Yee, KW,
Haley, AD,
Town, A
|
Leukemia |
2006 |
30862120 |
Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations-Possible Therapeutic Efficacy of Cabozantinib
Tien, HF,
Ko, YC,
Liu, ZH,
Hu, CY,
Chien, HF,
Lin, LI,
Ou, DL
|
Int J Mol Sci |
2019 |
22858906 |
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
Nguyen, B,
Brown, P,
Li, L,
Levis, M,
Williams, AB,
Leahy, D,
Small, D
|
Leukemia |
2013 |
29964125 |
Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases
Heinrich, MC,
Kent, JD,
Klug, LR
|
Pharmacol. Ther. |
2018 |
24227820 |
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Levis, M,
Small, D,
Cortes, J,
Ramachandran, A,
Galanis, A,
Rajkhowa, T,
Ma, H
|
Blood |
2014 |
29164965 |
The importance of FLT3 mutational analysis in acute myeloid leukemia
Patnaik, MM
|
Leuk. Lymphoma |
2018 |
28522571 |
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia
Jäkel, H,
Duyster, J,
Nachbaur, D,
Götze, KS,
Sill, H,
Taschler, M,
Hengst, L,
Podmirseg, SR,
Peschel, I
|
Haematologica |
2017 |